Literature DB >> 1912560

Infection of megakaryocytes by human immunodeficiency virus in seropositive patients with immune thrombocytopenic purpura.

F Louache1, A Bettaieb, A Henri, E Oksenhendler, J P Farcet, P Bierling, M Seligmann, W Vainchenker.   

Abstract

Twenty-one human immunodeficiency virus (HIV)-positive patients, including 11 acquired immunodeficiency syndrome (AIDS)-free patients with immune thrombocytopenic purpura (ITP), were studied to determine whether the megakaryocytic/platelet lineage was infected by HIV. Because purification of platelets did not reach a level sufficient for unequivocal results by the polymerase chain reaction, in situ hybridization was thus performed. Purified marrow megakaryocytes (MK) from 10 HIV-infected ITP patients were studied using a 35S HIV riboprobe, antisense of an HIV ENV sequence. HIV transcripts were clearly detected in MK from five of these 10 patients, although heterogeneity among MK was observed. In three of these five cases, small amounts of HIV glycoproteins were detected in MK by means of immunofluorescence. In addition anti-HIV antibodies could be eluted from platelets of all patients. In contrast, HIV transcripts were not detected in MK derived from colony-forming units-MK (CFU-MK) cultured in suspension, suggesting either that MK are infected by HIV during terminal differentiation or that HIV-infected CFU-MK are unable to differentiate in vitro. In conclusion, this study suggests that HIV infection of MK may be implicated in the pathogenesis of thrombocytopenia of HIV-positive patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1912560

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia.

Authors:  F Voulgaropoulou; B Tan; M Soares; B Hahn; L Ratner
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

Review 2.  Platelets and viruses: an ambivalent relationship.

Authors:  Claire Flaujac; Siham Boukour; Elisabeth Cramer-Bordé
Journal:  Cell Mol Life Sci       Date:  2009-12-12       Impact factor: 9.261

3.  Two subpopulations of human triple-negative thymic cells are susceptible to infection by human immunodeficiency virus type 1 in vitro.

Authors:  H Valentin; M T Nugeyre; F Vuillier; L Boumsell; M Schmid; F Barré-Sinoussi; R A Pereira
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

4.  Infection of hematopoietic progenitor cells by HIV-1 subtype C, and its association with anemia in southern Africa.

Authors:  Andrew D Redd; Ava Avalos; Max Essex
Journal:  Blood       Date:  2007-08-10       Impact factor: 22.113

5.  Haematological changes in HIV infection with correlation to CD4 cell count.

Authors:  Ss Parinitha; Mh Kulkarni
Journal:  Australas Med J       Date:  2012-03-31

Review 6.  Human immunodeficiency virus type 1 (HIV-1) and human hematopoietic progenitor cells.

Authors:  M C Re; G Furlini; G Zauli; M La Placa
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

Review 7.  Peering into the HIV reservoir.

Authors:  Marcial García; María J Buzón; José M Benito; Norma Rallón
Journal:  Rev Med Virol       Date:  2018-05-09       Impact factor: 6.989

Review 8.  Platelets and infection - an emerging role of platelets in viral infection.

Authors:  Alice Assinger
Journal:  Front Immunol       Date:  2014-12-18       Impact factor: 7.561

Review 9.  Oral manifestations of thrombocytopaenia.

Authors:  R A G Khammissa; J Fourie; A Masilana; S Lawrence; J Lemmer; L Feller
Journal:  Saudi Dent J       Date:  2017-09-23

10.  Hematological particularities and co-infections in injected drug users with AIDS.

Authors:  Denise Menezes Brunetta; Gil Cunha De Santis; Fernando Crivelenti Vilar; Renata Amorim Brandão; Renata Zomer de Albernaz Muniz; Geovana Momo Nogueira de Lima; Manuela Emiliana Amorelli-Chacel; Dimas Tadeu Covas; Alcyone Artioli Machado
Journal:  Braz J Infect Dis       Date:  2013-08-31       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.